Newest first
New topics page 31
Topics ordered by when they were created rather than by activity. This is where a question that nobody has answered yet is easiest to find — and answering one is the fastest route to a first solution badge.
1,535 topics · page 31 of 40
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Coming back to: Resolution and tailing factor: real acceptance criteria
Posting this under the heading it deserves: Resolution and tailing factor: real acceptance criteria Everything below is what sits behind that. Posting the method first, because I know what the first three…
|
+93 | 112 | 5.7k | 9mo |
|
[2026 update] What we do not know about retatrutide, listed explicitly
What we do not know about retatrutide, listed explicitly — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SCALE ( N Engl J Med , 2015) with STEP 2 ( Lancet ,…
|
+79 | 83 | 952 | 11mo |
|
Freeze-thaw and why one cycle is not the same as five — a second dataset
Freeze-thaw and why one cycle is not the same as five — a second dataset — setting out what I have, and where I think it stops being reliable. Practical question with the units stated, because I have seen how…
|
+47 | 55 | 46k | 10mo |
|
Adolescents: a distinct evidence base — one year on
Posting this under the heading it deserves: Adolescents: a distinct evidence base — one year on Everything below is what sits behind that. General question, not a request for advice about my own care — I know…
|
+78 | 88 | 9.3k | 3mo |
|
Pooling trials with different estimands — what changed since
Pooling trials with different estimands — what changed since — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SURPASS-4 ( Lancet , 2021) and finding…
|
+57 | 64 | 12k | 7mo |
|
Journal club: how we handle discontinuation in obesity trials
On the subject in the title: Journal club: how we handle discontinuation in obesity trials Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before…
|
2 | 1.9k | 12mo | |
|
Critiquing an observational claim about a class effect — one year on
Critiquing an observational claim about a class effect — one year on — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016) cited in support of a claim…
|
+5 | 9 | 3.2k | 8mo |
|
Revisiting: Food effects on oral incretin absorption: what is documented
Revisiting: Food effects on oral incretin absorption: what is documented — setting out what I have, and where I think it stops being reliable. Session topic: SURMOUNT-2 ( Lancet , 2023). Please read it before…
|
+6 | 10 | 51k | 13mo |
|
Second pass at: Robustness: the parameters worth deliberately varying
On the subject in the title: Second pass at: Robustness: the parameters worth deliberately varying Working notes rather than a conclusion. I would like to understand what this number means before I repeat it…
|
+61 | 66 | 9.5k | 3mo |
|
[2026 update] Cold solution and stinging: the simplest fix
Cold solution and stinging: the simplest fix — setting out what I have, and where I think it stops being reliable. Reporting something rather than asking about it, in case the pattern is useful to anyone…
|
+6 | 10 | 496 | 11mo |
|
Persistent vomiting and the threshold for seeking help
On the subject in the title: Persistent vomiting and the threshold for seeking help Working notes rather than a conclusion. General question, not a request for advice about my own care — I know the difference…
|
+82 | 88 | 31k | 7mo |
|
Pricing far outside the range, in either direction
Posting this under the heading it deserves: Pricing far outside the range, in either direction Everything below is what sits behind that. Structured report rather than an opinion, following the format the…
|
+3 | 7 | 27k | 7mo |
|
About the Side effects category
Recognition, grading, timeline, and management. Adverse events that need urgent attention belong in Safety. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…
|
4 | 7.1k | 13mo | |
|
[2026 update] Scheduled maintenance and what will be unavailable
Posting this under the heading it deserves: Scheduled maintenance and what will be unavailable Everything below is what sits behind that. Process question about how this site works. I have read the guidelines…
|
+18 | 22 | 400 | 8mo |
|
How to read a forest plot, properly, from scratch
The question in the title: How to read a forest plot, properly, from scratch I will give what I have already checked below so nobody repeats it. Session topic: STEP 4 ( JAMA , 2021). Please read it before…
|
+73 | 81 | 17k | 7mo |
|
Pages past their review date, listed
Pages past their review date, listed Writing it up because I had to work it out twice and would rather nobody else did. Nominating something for promotion into the documentation commons. The topic in question…
|
+26 | 30 | 6.4k | 10mo |
|
About the Dosing & titration category
Schedules, escalation intervals, dose reductions, and the arithmetic that connects a vial to a syringe mark. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…
|
4 | 350 | 4mo | |
|
"Greater than or equal to 99%" as a specification rather than a result
"Greater than or equal to 99%" as a specification rather than a result Writing it up because I had to work it out twice and would rather nobody else did. Working through the identity arithmetic and I would…
|
+132 | 146 | 47k | 5mo |
|
Second pass at: Import rules for personal quantities, by jurisdiction, dated
Second pass at: Import rules for personal quantities, by jurisdiction, dated Writing it up because I had to work it out twice and would rather nobody else did. A logistics question, since the answers here are…
|
2 | 5k | 11mo | |
|
About the Administration category
Technique, needle selection, site rotation, injection discomfort, and what to do about a missed or partial dose. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit…
|
+5 | 9 | 3.1k | 12mo |
|
Comparing the STEP programme populations: who was actually enrolled — the long version
On the subject in the title: Comparing the STEP programme populations: who was actually enrolled — the long version Working notes rather than a conclusion. Comparing PIONEER 6 ( N Engl J Med , 2019) with…
|
4 | 7.7k | 11mo | |
|
Area percent versus weight percent: the confusion that causes most arguments — what changed since
Area percent versus weight percent: the confusion that causes most arguments — what changed since Writing it up because I had to work it out twice and would rather nobody else did. Posting the method first,…
|
+30 | 34 | 40k | 13mo |
|
About the Tirzepatide category
Dual GIP/GLP-1 receptor agonist. SURPASS and SURMOUNT programme data, titration, and comparative discussion. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…
|
+2 | 6 | 132 | 13mo |
|
Interim analyses and stopping rules — does this still hold?
Interim analyses and stopping rules — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SCALE ( N Engl J Med , 2015) with SURMOUNT-4 (…
|
+30 | 34 | 29k | 13mo |
|
AOD-9604 and the fragment hypothesis, revisited
Posting this under the heading it deserves: AOD-9604 and the fragment hypothesis, revisited Everything below is what sits behind that. Comparing SURPASS-2 ( N Engl J Med , 2021) with SUSTAIN 6 ( N Engl J Med…
|
+40 | 44 | 2.8k | 6mo |
|
Why a compound being unapproved is not the same as being illegal to possess
Why a compound being unapproved is not the same as being illegal to possess I have a specific reason for asking rather than idle curiosity, and the context is below. Structured report rather than an opinion,…
|
+72 | 78 | 23k | 3mo |
|
When to stop reading forums, including this one
When to stop reading forums, including this one I have a specific reason for asking rather than idle curiosity, and the context is below. General question, not a request for advice about my own care — I know…
|
+78 | 86 | 47k | 6mo |
|
Coming back to: Why semaglutide solutions can look faintly opalescent and when that matters
Asking directly, because I could not find a straight answer: Why semaglutide solutions can look faintly opalescent and when that matters Comparing SELECT ( N Engl J Med , 2023) with PIONEER 6 ( N Engl J Med ,…
|
+16 | 20 | 17k | 13mo |
|
How this community escalates rather than diagnoses
How this community escalates rather than diagnoses — that is the question, and I have not found it answered plainly anywhere I have looked. Asking about a population rather than about a person. The published…
|
4 | 51k | 8mo | |
|
Why semaglutide's albumin binding is the whole reason weekly dosing works
Asking directly, because I could not find a straight answer: Why semaglutide's albumin binding is the whole reason weekly dosing works Session topic: SELECT ( N Engl J Med , 2023). Please read it before…
|
2 | 63k | 5mo |